John E. McKinnon - Concepedia

Author

John E. McKinnon

Also Known As

George Alangaden, Indira Brar, J McKinnon, J Mckinnon, J. E. McKinnon, J.E. Mckinnon, JOHN MCKINNON, John E McKinnon, John E. McKinnon, John Ernest McKinnon

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Henry Ford Hospital University of Pittsburgh University of Nebraska Medical Center Wayne State University Harvard University

About

John E. McKinnon is an author at Henry Ford Hospital specializing in medicine, clinical trials, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	353
2	Public Health	2	2	67
3	Epidemiology	2	2	67
4	Health Sciences	1	1	22
5	Emergency Medicine	1	1	40

John E. McKinnon

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 Samia Arshad, Paul E. Kilgore, Zohra Chaudhry, International Journal of Infectious Diseases	2020	564
Congestive Heart Failure and QRS Duration Heather J. Shenkman, Vijayamalini Pampati, Akshay K. Khandelwal, CHEST Journal Heart FailureCardiovascular DiseaseCardiac CareCongestive Heart FailureMedicine	2002	247
Regimen Simplification to Atazanavir‐Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48‐Week Clinical and Virologic Outcomes Timothy Wilkin, John E. McKinnon, A. Gregory DiRienzo, The Journal of Infectious Diseases	2009	53
Outcomes and Prognostic Factors of Systolic as Compared With Diastolic Heart Failure in Urban America Peter A. McCullough, Akshay Khandelwal, John E. McKinnon, Congestive Heart Failure Prognostic FactorsHeart FailureLarge Heart FailureBlood PressureDiastolic Function	2005	40
Descriptive Analysis of Patients Living With HIV Affected by COVID-19 Smitha Gudipati, Indira Brar, Shannon L. Murray, JAIDS Journal of Acquired Immune Deficiency Syndromes	2020	39
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery Anthony R. Cillo, Benedict B. Hilldorfer, Christina M. Lalama, AIDS	2015	32
Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis Joseph A. Ladapo, John E. McKinnon, Peter A. McCullough, Controlled TrialsPharmacotherapyCovid-19 EpidemiologyCovid-19Preventive Medicine	2020	27
Potential Risks and Benefits of HIV Treatment Simplification: A Simulation Model of a Proposed Clinical Trial Bruce R. Schackman, Catherine A. Scott, Paul E. Sax, Clinical Infectious Diseases	2007	25
Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes Yi Yao, Kalpana Subedi, Tingting Liu, Cell Discovery	2022	25
Safety and Tolerability of 514G3, a True Human Anti-Protein A Monoclonal Antibody for the Treatment of S. aureus Bacteremia Toan T. Huynh, Michael Stecher, John E. McKinnon, Open Forum Infectious Diseases Medical MicrobiologyAntimicrobial SusceptibilityHealth SciencesS. Aureus BacteremiaPathogenesis	2016	22

Page 1